GR 20263, a new broad-spectrum cephalosporin with anti-pseudomonal activity.
about
Crystal Structures of Penicillin-Binding Protein 3 from Pseudomonas aeruginosa: Comparison of Native and Antibiotic-Bound FormsComparison of ceftazidime with cefamandole for therapy of community-acquired pneumoniaComparative pharmacokinetics of azlocillin and piperacillin in normal adults.Altered pharmacokinetics of ceftazidime in critically ill patients.Characterization of ceftazidime resistance mechanisms in clinical isolates of Burkholderia pseudomallei from Australia.The evolving role of chemical synthesis in antibacterial drug discovery.Development and evaluation of a Bayesian pharmacokinetic estimator and optimal, sparse sampling strategies for ceftazidime.Pharmacokinetics and penetration of ceftazidime and avibactam into epithelial lining fluid in thigh- and lung-infected mice.Ceftazidime as single-agent therapy for gram-negative aerobic bacillary osteomyelitisCeftazidime as initial therapy for suspected bacterial infections in hospitalized pediatric patients.In vitro activity of DQ-2556, a new cephalosporin.In vitro and in vivo antibacterial activities of carumonam (AMA-1080), a new N-sulfonated monocyclic beta-lactam antibiotic.Randomized, double-blind comparison of ceftazidime and moxalactam in complicated urinary tract infections.Randomized evaluation of ceftazidime or ticarcillin and tobramycin for the treatment of osteomyelitis caused by gram-negative bacilli.BRL 17421, a novel beta-lactam antibiotic, highly resistant to beta-lactamases, giving high and prolonged serum levels in humans.Comparative in vitro study of temocillin (BRL 17421), a new penicillin.Ceftriaxone: in vitro studies and clinical evaluationPharmacokinetics of ceftazidime in male and female volunteersPenetration of ceftazidime into cerebrospinal fluid of patients with bacterial meningitis.Use of ceftazidime in the therapy of serious infections, including those due to multiresistant organisms.Properties of PSE-2 beta-lactamase and genetic basis for its production in Pseudomonas aeruginosa.Distribution of ceftazidime in ascitic fluidSynergism between aminoglycosides and cephalosporins with antipseudomonal activity: interaction index and killing curve method.Ceftazidime therapy of serious bacterial infections.In vitro and in vivo antibacterial activities of E1077, a novel parenteral cephalosporinComparative pharmacokinetics and serum bactericidal activities of SCE-2787 and ceftazidime.In vitro and in vivo activities of SCE-2787, a new parenteral cephalosporin with a broad antibacterial spectrumIn vitro evaluation of GR69153, a novel catechol-substituted cephalosporin.Disk diffusion susceptibility test interpretive criteria for GR69153, a new catechol-substituted cephalosporin.Disk agar diffusion susceptibility testing with 30-micrograms ceftazidime disks: confirmation of interpretive breakpoints and quality control guidelines.Cefoperazone disk diffusion susceptibility test: confirmation of the tentative interpretive criteria, Pseudomonas aeruginosa cross-resistance, and determination of quality control performance limits.Cephalosporins in cutaneous infections. A prospective comparison of two dosage regimens of ceftazidime for therapy of skin and skin structure infections.In vitro activity of CGP 31523A, a broad-spectrum cephalosporin, in comparison with those of other agents.In vitro and in vivo activities of DN-9550, a new broad-spectrum cephalosporin.Comparison of in vitro activities of eight beta-lactamase-stable cephalosporins against beta-lactamase-producing gram-negative bacilli.Activity of ceftazidime (GR 20263) against nosocomially important pathogens.Comparison of ceftazidime and cefamandole pharmacokinetics and blister fluid concentrations.Comparative multiple-dose pharmacokinetics of cefotaxime, moxalactam, and ceftazidime.Antibacterial activity and beta-lactamase stability of ceftazidime, an aminothiazolyl cephalosporin potentially active against Pseudomonas aeruginosa.In vitro activity of cefotetan, a new cephamycin derivative, compared with that of other beta-lactam compounds.
P2860
Q27665349-AA2EC15B-CDC8-4244-AE0B-A7493F6076FCQ30451309-5AC94452-EA7C-429D-9CF4-8792486B3BBDQ33739915-9AF5CC7C-1388-4122-8F84-0783893C6DABQ33977268-2508EA0F-C38C-4D5A-8584-C73741371973Q34170246-7F0D7DF4-DE47-46B8-B9B7-96FAACE2A9B8Q34427652-A804B427-1F0A-4755-AE7C-AF4E99A71636Q35126112-32A11A46-08B6-4843-B146-B26C80408C43Q35168955-EB5DAC69-9359-47A4-BAA5-9557110869FDQ35542719-0FF7680B-5910-403D-A10C-B94F7F172409Q35568218-731EF252-5024-44CC-BD35-4E126F97D23AQ35575411-91303466-837C-4506-855D-759552DA8FF0Q35644656-6FD6DD6D-8EFD-45F4-8D71-6C299F7A1EC6Q35646344-323430CA-C996-476A-AFFA-A1051C4DD7ADQ35648514-174C80C5-EDEB-4586-9CBA-ADC556B1C920Q35670880-0762CB22-D92B-40C9-9B02-7B0DAB7F9668Q35675199-C9A89776-7429-4D82-B591-4D22EF645104Q35712352-1DCEE5F1-944B-40DC-A1CC-7C65EBA73594Q35745171-B85A2B43-F848-468E-9316-E651B51BB0EAQ35748951-863678DE-B94C-41B3-B0CB-6602D2627B9EQ35749310-318364C3-4799-4683-BF80-46A89A30EB08Q35754029-A6D76C3A-60F6-46C7-ABF9-6D0978B07186Q35760774-A3CCD882-3861-4616-A22F-0774B46A2D35Q35761083-DF8E2699-E31F-44AB-9121-2433FEA0F4B4Q35769557-CA40AD25-EA92-419A-931C-07B9AB884466Q35807617-4632A2FE-926C-4754-9484-16D592289C69Q35819061-690667DF-13E7-4181-BC8B-487515A1CEB7Q35884688-C774C9AD-A47B-417C-ACC5-2928A726A9F1Q36753812-F920884A-F743-4792-AFA5-61EA1F53BAEEQ37247379-27F754C5-8FEE-4EA7-B4A7-34A4F51F51A9Q37254755-3C69E47C-E7EA-485F-B5F6-6E1D13EE4C13Q37291928-B5681850-6E88-4B6A-9B72-8BB403EC5DA5Q39104856-3301D5E8-89AF-4EEE-A404-549F6449EEFAQ39849432-2E79E89C-ED22-4203-8DB7-7C79D7188940Q39849584-F4929B11-6C9C-4A43-80EE-C6FE50FA26F6Q39854709-C81775F2-AEFF-4938-BED0-113AB7804C89Q39855329-24F92FE8-9BB2-4395-BD87-207BC8992506Q39855737-4096B228-9A3C-4AA6-BDBE-923AA5702428Q39855972-D8102A45-CB1C-4CB6-A54C-C7E480268965Q39856285-EEA822DA-D3EE-49ED-9C1D-A8E0A024C2CFQ39856694-7E7640D7-F027-4D57-A97F-D0D964A769F9
P2860
GR 20263, a new broad-spectrum cephalosporin with anti-pseudomonal activity.
description
1980 nî lūn-bûn
@nan
1980 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
1980 թվականի մայիսին հրատարակված գիտական հոդված
@hy
1980年の論文
@ja
1980年論文
@yue
1980年論文
@zh-hant
1980年論文
@zh-hk
1980年論文
@zh-mo
1980年論文
@zh-tw
1980年论文
@wuu
name
GR 20263, a new broad-spectrum cephalosporin with anti-pseudomonal activity.
@ast
GR 20263, a new broad-spectrum cephalosporin with anti-pseudomonal activity.
@en
type
label
GR 20263, a new broad-spectrum cephalosporin with anti-pseudomonal activity.
@ast
GR 20263, a new broad-spectrum cephalosporin with anti-pseudomonal activity.
@en
prefLabel
GR 20263, a new broad-spectrum cephalosporin with anti-pseudomonal activity.
@ast
GR 20263, a new broad-spectrum cephalosporin with anti-pseudomonal activity.
@en
P2093
P2860
P356
P1476
GR 20263, a new broad-spectrum cephalosporin with anti-pseudomonal activity.
@en
P2093
P2860
P304
P356
10.1128/AAC.17.5.876
P407
P577
1980-05-01T00:00:00Z